<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">COSYNTROPIN</span><br/>(koe-sin-troe'pin)<br/><span class="topboxtradename">Cortrosyn<br/></span><b>Classifications:</b> <span class="classification">diagnostic agent</span><br/><b>Prototype: </b>Prednisone<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic polypeptide resembling corticotropin (ACTH) in relation to the first 24 of the 39 amino acids in naturally occurring
         ACTH. Has less immunologic activity and is associated with less risk of sensitivity than corticotropin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In patient with normal adrenocortical function, stimulates adrenal cortex to secrete corticosterone, cortisol (hydrocortisone),
         several weak androgenic substances, and limited amounts of aldosterone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Diagnostic tool to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>In patients with normal adrenocortical function for the long-term treatment of chronic inflammatory or degenerative disorders
         responsive to glucocorticoids.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of allergic disorders; scleroderma, osteoporosis; systemic fungal infections, ocular herpes simplex; recent surgery;
         history of or presence of peptic ulcer; CHF; hypertension; adrenocortical insufficiency and adrenocortical hyperfunction;
         pregnancy (category C), lactation; immunizations, tuberculosis, infections.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Multiple sclerosis, acute gouty arthritis, mental disturbances, diabetes, abscess, pyrogenic infections, diverticulitis, renal
         insufficiency, myasthenia gravis, children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Rapid Screening Test</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">
<i>&gt;2 y: </i>IM/IV</span> 0.25 mg injected over 2 min<br/><span class="rdage">Child:</span> <span class="rdroute">
<i>IM</i></span> 0.125 mg injected over 2 min; <span class="rdroute">IV</span> 0.125 mg at 0.04 mg/h over 6 h<br/><span class="rdage">Neonate:</span> <span class="rdroute">IM/IV</span> 0.015 mg/kg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute cosyntropin powder by adding 1.1 mL NS (diluent provided by manufacturer) to vial labeled 0.25 mg to provide
            solution containing 0.25 mg/mL.
         </li>
<li>Inject deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants and children: Verify correct IV concentration and rate of infusion/injection with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute as for IM.   <span class="methodtype">IV Infusion:</span>  Further dilute in 250500 mL of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 2 min.   <span class="methodtype">IV Infusion:</span>  Give at an approximate rate of 40 mcg/h over 46 h.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Reconstituted solutions remain stable 24 h at room temperature or 21 d at 2°8° C.</li>
<li>Cosyntropin should not be added to blood or to plasma infusions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Mild fever. <span class="typehead">GI:</span> chronic pancreatitis. <span class="typehead">Skin:</span> Pruritus. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<b>Cortisone,</b>
<b>hydrocortisone,</b>
<b>estrogen,</b>
<b>spironolactone</b> elevated <span class="alt">bilirubin,</span> and presence of <span class="alt">free Hgb</span> in plasma may interfere with <span class="alt">plasma cortisol</span> determinations.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cortisone,</b>
<b>hydrocortisone</b> can exhibit abnormally high baseline values of cortisol and a decreased response to cosyntropin test. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Plasma cortisol levels double in 1530 min. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead"> Distribution:</span>  Unknown; does not cross placenta. <span class="typehead">Metabolism:</span> Unknown. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Normal 17-KS levels in men are 1025 mg/24 h; in women 50 y, 48 mg/24 h.</li>
<li>Normal 17-OHCS levels in men are 512 mg/24 h; in women, 310 mg/24 h; in children 812 y, 
      </li></ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>